title: Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
authors.forename: Herman
authors.initials: H
authors.lastname: Burger
authors.forename: Ron H J
authors.initials: RH
authors.lastname: Mathijssen
authors.forename: Alex
authors.initials: A
authors.lastname: Sparreboom
authors.forename: Erik A C
authors.initials: EA
authors.lastname: Wiemer
mesh_terms: D000547:Amantadine / Q000494:pharmacology*; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001549:Benzamides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001693:Biological Transport, Active / Q000187:drug effects; D045744:Cell Line, Tumor; D057809:HEK293 Cells; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism*; D027702:Organic Cation Transporter 1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D010879:Piperazines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011743:Pyrimidines / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D018712:Analgesics, Non-Narcotic; D000970:Antineoplastic Agents; D001549:Benzamides; D027702:Organic Cation Transporter 1; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000547:Amantadine